Thymalin Moderate Evidence

What It Is

Thymalin (Russian: Тималин; transliterated also as "Timalin") is a parenteral polypeptide preparation manufactured from the thymus glands of calves by controlled mild acid extraction followed by acetone fractionation. The end product is a lyophilized white-to-cream powder of low-molecular-weight peptides with molecular weights below approximately 10 kilodaltons. It is not a single defined-structure peptide; it is a complex polypeptide fraction whose biological activity reflects the combined contribution of many short peptide species released by gland processing. In regulatory terms it sits in the same category as Cerebrolysin — a biological extract rather than a synthetic single-molecule pharmaceutical.

The drug was developed in the 1970s at the Military Medical Academy named after S.M. Kirov in Leningrad (now St. Petersburg) by V.G. Morozov and V.Kh. Khavinson, originally under a Soviet Ministry of Defense commission to develop interventions for soldiers exposed to radiation, chemical injury, and severe trauma. The development line subsequently moved with Khavinson to the St. Petersburg Institute of Bioregulation and Gerontology, where the broader family of "peptide bioregulators" (Thymalin, Epithalamin, Cortexin, Prostatilen, Retinalamin, Vladonix, and others) was elaborated over the following decades. Thymalin received Russian Ministry of Health registration as an immunomodulating drug in 1982 and has remained in continuous clinical use since.

Thymalin is not the same compound as several other "thymic" peptides commonly mentioned in the same conversation, and these distinctions matter:

• Thymosin alpha-1 (Tα1) — A defined-structure synthetic 28-amino-acid peptide originally isolated from bovine Thymosin Fraction 5; marketed internationally as Zadaxin (thymalfasin). It is a single, fully characterized molecule with FDA orphan-drug status and broad ex-US approvals. Mechanistically overlapping (T-cell maturation, NK restoration), but pharmacologically and regulatorily distinct.
• Thymopentin (TP-5) — A synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to active residues 32–36 of thymopoietin. Defined structure, distinct compound, distinct development lineage.
• Thymogen — A synthetic dipeptide (L-Glu-L-Trp) that the Khavinson group isolated from Thymalin by reversed-phase HPLC and subsequently synthesized as a single defined-structure molecule. Thymogen is therefore a "child" of Thymalin in the bioregulator family — a synthetic short peptide derived from one of Thymalin's active components — but it is itself a different drug, regulatorily and pharmaceutically separable.
• Vilon (Lys-Glu), Bestim, and other Khavinson-family thymic short peptides — Defined-structure synthetic di- and tripeptides developed in the same lineage. Different molecules.

The Khavinson group's working theoretical frame is that Thymalin's biological activity is dominated by a small number of short peptide motifs released within the complex — particularly the dipeptides Glu-Trp (EW) and Lys-Glu (KE) and the tripeptide Glu-Asp-Pro (EDP) — which the group hypothesizes can penetrate cell and nuclear membranes and modulate gene expression by direct interaction with promoter-region DNA and with histone proteins. This "short peptide DNA-binding" hypothesis is the central mechanistic claim of the Khavinson research school and is articulated across reviews including Khavinson & Popovich (2017) and the systematic peptide-regulation reviews indexed in PubMed (PMID 27909961; PMID 31808038).

Mechanism of Action

The mechanistic literature on Thymalin reflects four-plus decades of research, almost entirely from the Khavinson group and its collaborators. The principal claims, with their most-cited supporting findings:

• T-cell maturation enhancement — Thymalin promotes maturation and differentiation of CD3+ thymocytes into CD4+ helper and CD8+ cytotoxic T-cell subpopulations. In aged or immunosuppressed subjects, the predominant finding is a normalization (rather than blanket stimulation) of T-cell subsets — the drug behaves as an immunomodulator that returns deviant parameters toward physiological reference rather than uniformly raising them. This is the foundational pharmacological claim and underpins the Russian regulatory "immunomodulator" category.
• CD4/CD8 ratio normalization — In age-related immunosenescence and post-infection immunosuppression, the CD4/CD8 ratio is typically distorted (often inverted in advanced age and chronic viral infection). Thymalin courses are reported in Russian literature to restore CD4/CD8 ratios toward a healthier range in elderly and post-viral cohorts (Khavinson & Morozov 2003, PMID 14523363).
• NK cell cytolytic activity restoration — Natural killer cell counts and cytolytic function are reported to recover after Thymalin courses in immunosuppressed subjects. The Kuznik et al. severe-COVID-19 cohort reported restoration of NK cell subpopulations alongside lymphocyte recovery.
• IL-2 and interferon production normalization — Thymalin restores IL-2 production by peripheral blood lymphocytes in subjects with documented baseline depression of IL-2 secretion. Interferon system effects are reported in the older Russian literature; both findings are consistent with a thymopoietic / T-cell-maturation mode of action (Morozov & Khavinson 1997, PMID 9637345).
• Hypothalamic-pituitary-thymus axis modulation — The Khavinson group reports that Thymalin courses are associated with normalization of ACTH, TSH, and cortisol patterns alongside immune normalization in elderly subjects, consistent with the bioregulator hypothesis that the thymus is part of a coupled neuroendocrine-immune axis (Khavinson & Morozov 2003).
• Pineal-thymus crosstalk — Khavinson long-cohort observational data combine Thymalin with the pineal complex Epithalamin, with the largest mortality reductions seen in the combination arm. The mechanistic hypothesis is bidirectional: pineal melatonin tone influences thymic function, and thymic peptide signaling reciprocally influences pineal output. The combination reportedly gives larger physiological effects than either complex alone.
• Hematopoietic stem cell differentiation — Khavinson and Linkova (Bull Exp Biol Med 2020, PMID 33237528) reported that Thymalin activates differentiation of human hematopoietic stem cells toward the lymphoid lineage in vitro, providing a candidate mechanism for the drug's reported activity in radiation- and chemotherapy-induced hematopoietic depression.
• Anti-inflammatory cytokine modulation — Avolio et al. (PMID 35408963) demonstrated in the human THP-1 monocyte/macrophage cell line that Thymalin (alongside Epitalon, Vilon, Thymogen, and Chonluten) reduced TNF-α, IL-1β, and IL-6 release and reduced LPS-induced adhesion to activated HUVEC endothelium — describing the Khavinson family as inducers of TNF tolerance in monocytes and as anti-inflammatory modulators of macrophage activity.
• Hemostatic system normalization — Russian literature including Kuznik et al. attributes to Thymalin a normalization of platelet aggregation and fibrinolytic balance in subjects with disturbed coagulation; the COVID-era trial program rests in part on this dual immune + hemostatic effect (relevant to thrombo-inflammatory cytokine storm pathology). The 1986 thymectomy/platelet study (Kuznik, Morozov, Khavinson; PMID 3754821) is the early experimental anchor for this thymus-platelet-axis literature.
• Khavinson short-peptide DNA-binding hypothesis — The Khavinson group's overarching mechanistic frame proposes that the pharmacologic activity of Thymalin is largely mediated by a small number of short peptide fragments released from the complex (most prominently Glu-Trp / EW, Lys-Glu / KE, and Glu-Asp-Pro / EDP), which are hypothesized to penetrate the nuclear envelope and interact directly with promoter-region DNA, modulating transcription of genes related to T-cell maturation, immunoregulation, and hemostasis. The DNA-binding component remains contested in the wider biochemical literature; the gene-expression modulation observed in Khavinson-group experimental systems is reproducible within those laboratories but has only limited independent replication.
• Multi-component, multi-target profile — Like Cerebrolysin, Thymalin's pharmacology cannot be collapsed to a single receptor or pathway. It should be read as a polypeptide preparation whose net effect is the integral of many small contributions, with the empirical signature being immunomodulation rather than uniform immunostimulation.

What the Research Shows

Thymalin's research base spans more than four decades and several thousand Russian-language publications, with a smaller subset of English-language peer-reviewed reports. The signal is consistent across applications, but the evidence quality is uneven and heavily concentrated in one research school.

• Immunosenescence in the elderly — The most-cited human dataset is the Khavinson & Morozov 6–8-year geroprotective trial in 266 elderly persons (PMID 14523363, PMID 12577695). Repeated annual short courses of Thymalin (with or without Epithalamin) were associated with normalization of immune (T- and B-cell subsets, phagocytosis), endocrine (ACTH, TSH, insulin), and metabolic parameters; with reduced incidence of acute respiratory infection (2.0–2.4-fold), ischemic heart disease manifestations, hypertension, and osteoarthrosis; and with mortality reductions of 2.0–2.1-fold (Thymalin alone), 1.6–1.8-fold (Epithalamin alone), and 2.5-fold (combination) versus untreated controls — with a sub-cohort treated annually with the combination for six years showing a 4.1-fold mortality reduction.
• Post-viral and post-infectious immune restoration — Russian clinical reports describe Thymalin courses for patients recovering from viral pneumonia, herpes-virus reactivation, and bacterial infections complicated by immunosuppression. Reported effects include lymphocyte subset normalization, faster clinical recovery, and reduced relapse frequency. Most of these reports predate modern reporting standards and should be read as historical evidence rather than confirmatory RCTs.
• Pulmonary disease adjunct — Lukyanov et al. (International Journal of Immunology and Immunotherapy 2020) reported on Thymalin in severe SARS-CoV-2 pneumonia, with an early case showing rapid clinical improvement and reduced oxygen requirement following the addition of Thymalin to standard care. The 2021 Khavinson group review (Front Pharmacol; PMC8365293) summarizes Thymalin's reported activity in pulmonary infection, lung abscess, and pneumonia recovery.
• COVID-19 — severe-cohort trial — Kuznik, Khavinson, Shapovalov et al. ("Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients", Adv Gerontol 2021) reported on older patients with severe COVID-19 enrolled at the Affiliated Hospital of Chita State Medical Academy under IRB approval (protocol no. 102, 15 May 2020). The Thymalin arm showed accelerated reversal of lymphopenia, recovery of platelet/lymphocyte ratio, and recovery of CD3+HLA-DR+, CD4+, B-, and NK-cell subpopulations relative to standard care, with reported reduction of in-hospital mortality.
• Adaptive immunity and antibody response — Khavinson, Kuznik, Volchkov et al. ("Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19", Klinicheskaya Meditsina 2020, vol 98, no 8, pp 593–599) reported comparative IgG-to-SARS-CoV-2 dynamics in patients receiving Thymalin alongside standard care vs standard care alone, suggesting an effect on the adaptive antibody response.
• Geroprotection and longevity — Aside from the 266-patient elderly cohort, Khavinson-group publications also report carcinogenesis attenuation in C3H/Sn mice with low-MW thymic, pineal, and hypothalamic peptide factors (Anisimov, Khavinson, Morozov; Mech Ageing Dev 1982), supporting the broader "peptide bioregulator" geroprotection narrative.
• Mechanistic in vitro work — Avolio et al. (PMID 35408963) provides an Italian-collaboration human-cell mechanistic study of Thymalin and four other Khavinson peptides in the THP-1 monocyte/macrophage line, finding reduced inflammatory cytokine release and reduced endothelial adhesion. This is one of the strongest non-Russian-group mechanistic confirmations available.
• Thymalin and stem cell differentiation — Khavinson, Linkova et al. (Bull Exp Biol Med 2020, PMID 33237528) reported that Thymalin activates differentiation of human hematopoietic stem cells, supporting the proposed mechanism for hematopoietic-recovery applications.
• Hemostatic effects — Older Russian work (Kuznik, Makhakova, Morozov, Pisarevskaya, Khavinson, PMID 3754821) characterized Thymalin's effect on platelet aggregation in intact and thymectomized rats, an early piece of the "thymus-hemostasis axis" literature the Khavinson group continues to develop.
• Inflammatory disease adjunct — Russian reports describe adjunctive Thymalin in inflammatory pulmonary, gastrointestinal, and dermatologic disorders. These reports are heterogeneous in design and are best read as early-phase clinical signal rather than confirmatory data.

Human Data

Thymalin's human evidence base is unusually large by total cumulative person-years (forty-plus years of post-marketing exposure in Russia and the post-Soviet space), but unusually narrow by sociology of authorship. The most clinically informative published reports:

• Khavinson & Morozov 2003 (PMID 14523363) — 266 elderly (60+) subjects across St. Petersburg and Kiev gerontology centers, allocated to one of four arms: control, Thymalin, Epithalamin, or Thymalin + Epithalamin combination. Bioregulators were administered intramuscularly at 10 mg per dose for 10 days per course (100 mg per course) annually for 2–3 years; subjects were followed for 6–8 years. Outcomes included improvement in cardiovascular, endocrine, immune, and nervous system indices; reduction in age-associated disease incidence; and mortality reductions of 2.0-fold (Thymalin alone) and 4.1-fold (combination, six annual courses) vs untreated controls. The single most-cited Thymalin clinical paper.
• Khavinson & Morozov 2002 — Adv Gerontol (PMID 12577695) — Russian-language companion publication of the geroprotective trial.
• Khavinson, Kuznik, Ryzhak 2013 (PMID 24003726) — Russian-language Adv Gerontol review summarizing long-term clinical results across the bioregulator family (Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin) for prevention of age-related disease.
• Kuznik, Khavinson, Shapovalov et al. 2021 — severe COVID-19, Adv Gerontol — Single-center (Affiliated Hospital of Chita State Medical Academy) trial in older patients with severe COVID-19. Thymalin was added to standard care; the Thymalin arm showed faster reversal of lymphopenia, restoration of CD3+HLA-DR+, CD4+, B- and NK-cell subpopulations, recovery of platelet/lymphocyte ratio, and reduced in-hospital mortality vs standard care alone. IRB-approved protocol no. 102, 15 May 2020.
• Khavinson, Kuznik, Volchkov et al. 2020 — Klinicheskaya Meditsina — Effect of Thymalin on adaptive immunity in COVID-19 complex therapy; reports comparative IgG-to-SARS-CoV-2 dynamics with vs without Thymalin.
• Lukyanov, Kuznik, Shapovalov, Khavinson et al. 2020 — Int J Immunol Immunother 7:055 — Severe COVID-19 case treated with Thymalin 10 mg IM daily after failed standard care, with marked early clinical improvement.
• Khavinson, Kuznik, Tarnovskaya, Linkova 2021 — Stem Cell Rev Rep (PMID 33575961) — Review proposing thymic peptides (Thymalin and short-peptide derivatives) for COVID-19 immunorehabilitation based on hematopoietic stem cell differentiation effects.
• Khavinson, Linkova et al. 2020 — Bull Exp Biol Med (PMID 33237528) — Demonstrates Thymalin activation of human hematopoietic stem cell differentiation, providing in vitro mechanistic support for clinical observations in immunorehabilitation.
• Khavinson, Linkova, Kvetnoy et al. 2021 — Frontiers in Pharmacology (PMC8365293) — "The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity" — narrative review summarizing 6–12-year Russian clinical data on Thymalin in pulmonary infection, viral disease, immunodepression after radiation and chemotherapy, and geroprotection.
• Khavinson 2002 — Neuro Endocrinol Lett (PMID 12374906) — "Peptides and Ageing" — narrative review noting that among Thymalin's effects, immune-stimulating activity is the most prominent.

Cumulative cohort experience implied by Russian post-marketing data runs into hundreds of thousands of patient-courses across the 1982–2026 period, but no large independent western RCT confirms the headline outcomes. Read the human dataset as: long, deep, and consistent within a single research school and regulatory jurisdiction; thin and largely absent outside it.

Dosing from the Literature

Thymalin is supplied in Russia as a lyophilized powder (typically 10 mg per vial) for parenteral administration after reconstitution with 0.9% sodium chloride or 0.5% procaine solution. The following dosing patterns summarize Russian clinical and Khavinson-group protocols. Self-administration of imported Thymalin is illegal in the United States; Thymalin is not legally compounded by U.S. compounding pharmacies.

Reconstitution & Storage

Thymalin is supplied as a lyophilized white-to-cream powder, typically in 10 mg single-use vials. Reconstitution with 0.9% sodium chloride is the most common protocol; some Russian formularies historically specified 0.5% procaine (novocaine) to reduce IM injection-site discomfort. The following table summarizes practical reconstitution scenarios for the standard 10 mg vial.

• Diluent — 0.9% sodium chloride is standard. 0.5% procaine has historical use in Russian formularies for IM administration to reduce injection-site discomfort; bacteriostatic water for injection (BAC water) is the practical research-use diluent.
• Reconstitution technique — Inject diluent slowly down the inside wall of the vial; gently swirl (do not shake) until the powder fully dissolves. Solution should be clear or slightly opalescent and colorless. Discard if cloudy or discolored.
• Storage — lyophilized — Sealed vials stored at 2–8 °C protected from light. Manufacturer shelf life is typically 2 years from manufacture.
• Storage — reconstituted — Refrigerate at 2–8 °C; use within 14–28 days for research-context handling. Russian clinical practice typically reconstitutes immediately before each daily dose and discards any residual.
• Do not freeze — Freezing the reconstituted solution may damage the polypeptide fraction. Do not microwave or expose to elevated temperatures.
• Inspection — Discard if any visible particulate, precipitate, cloudiness, or discoloration appears in the reconstituted vial.
• Compounded purity caveat — Research-supplier "Thymalin" sourced outside the Samson-Med (Russia) manufacturing chain may not match the original biological-extract specification. As a polypeptide complex (not a defined-structure peptide), Thymalin's identity cannot be confirmed by mass spectrometry alone — process characterization is required. Source identity verification matters more for Thymalin than for a single-molecule peptide.

→ Use the Kalios Dosing Calculator for Thymalin reconstitution math

Side Effects & Risks

Thymalin's safety profile in Russian post-marketing experience is benign across decades of clinical use, including in elderly and frail populations. The Russian product information lists hypersensitivity to the drug as the principal contraindication. Risks worth noting:

• Hypersensitivity reactions — Bovine-derived polypeptide preparations carry inherent risk of sensitization and allergic reaction in predisposed subjects. Patients with known allergy to bovine proteins, atopic disease, or prior reaction to thymic preparations should not receive Thymalin. First administration should occur in a clinical setting with monitoring for acute hypersensitivity (urticaria, angioedema, bronchospasm, anaphylaxis). Russian post-marketing experience reports such events as rare but biologically plausible given the source material.
• Injection-site reactions — Mild pain, erythema, and induration with intramuscular administration are the most commonly reported adverse events. Typically self-limiting; the historical use of 0.5% procaine as diluent in Russian formularies reflects an effort to minimize injection-site discomfort.
• Theoretical autoimmune risk — Immunomodulation in subjects with active or predisposed autoimmune disease (rheumatoid arthritis, systemic lupus erythematosus, Hashimoto thyroiditis, multiple sclerosis, type 1 diabetes) carries theoretical risk of disease flare. Russian clinical experience does not document a clear autoimmune-flare signal, but the absence of large prospective data in autoimmune cohorts is genuine. Use with caution in autoimmune subjects.
• Pregnancy and lactation — Insufficient human safety data; Russian product information advises against use in pregnancy and during breastfeeding except under direct clinician oversight where benefit outweighs risk.
• Pediatric use — Used in pediatric Russian protocols for immunodeficiency and post-infection immune restoration; doses are weight- and age-adjusted (commonly 1 mg/day for 1–6 years and 1–3 mg/day for 7–14 years).
• Source / purity concerns (research supply) — Thymalin is a polypeptide complex extracted from bovine tissue. Research-supplier products labeled "Thymalin" may not match the original Samson-Med biological-extract specification, may have undisclosed contaminants, and may not undergo equivalent prion-clearance and viral-inactivation processing applied in regulated pharmaceutical manufacture. The U.S. has a robust regulatory framework for clinical-grade biological extracts; research-supplier material is outside that framework and identity / safety cannot be assumed.
• Bovine source — TSE / prion-safety considerations — Bovine spongiform encephalopathy and related transmissible spongiform encephalopathies are the principal historical safety concern for any bovine-tissue-derived biological. Russian regulated manufacture of Thymalin involves source-herd controls and processing steps intended to mitigate TSE risk; decades of clinical use in Russia have not surfaced TSE/CJD signals attributable to Thymalin. Research-supplier material outside that regulated chain has no equivalent assurance.
• Drug interactions — No clinically significant pharmacokinetic interactions are documented in Russian product information. Caution is advised when combining Thymalin with other immunomodulating drugs (corticosteroids, calcineurin inhibitors, monoclonal antibody immunotherapies, other thymic peptides) — interactions are not characterized in modern pharmacology databases.
• Long-term safety — Forty-plus years of post-marketing use in Russia with no novel long-term safety signal surfaced; cumulative-dose dose-response data is limited and most clinical use is cyclical short-course (5–10 days) repeated periodically rather than continuous chronic dosing.
• WADA caution — Thymalin is not specifically named on the current WADA Prohibited List, but a thymic polypeptide complex with claimed effects on hematopoietic stem cell differentiation, T-cell maturation, and immune function could plausibly be evaluated under broader category language. Athletes subject to WADA testing should consult their sport federation prior to any use.
• No large western pharmacovigilance database — Unlike compounds approved in the EU or US, Thymalin has no FAERS or EudraVigilance equivalent. Adverse-event signal detection rests on Russian Ministry of Health reporting and Khavinson-group post-marketing surveillance; the absence of signal cannot be interpreted with the same confidence as a FAERS-derived absence-of-signal.

Bloodwork & Monitoring

Thymalin is administered in Russia under clinician supervision; bloodwork follows the underlying indication's clinical pathway. For research-context awareness:

• Baseline CBC with differential — Total WBC, lymphocyte count, neutrophil count, platelet count. Where available, lymphocyte subset panel (CD3, CD4, CD8, CD19, CD16/56) before and after each Thymalin course to track the principal pharmacodynamic endpoints described in the Khavinson literature.
• Baseline CMP — Renal (BUN, creatinine, eGFR) and hepatic (AST, ALT, total bilirubin, alkaline phosphatase, GGT) function. Thymalin has no documented hepato- or nephrotoxic signal but baseline panels are standard practice for any parenteral biological.
• Inflammatory markers — CRP and ESR baseline and at end-of-cycle to track inflammatory disease activity in indications where Thymalin is used adjunctively.
• Immunoglobulins — IgG, IgA, IgM baseline where available, and end-of-cycle in subjects with humoral immunodeficiency or recurrent infection.
• Autoimmune screen — In subjects with personal or family history of autoimmune disease, ANA, RF, anti-CCP, anti-TPO, anti-dsDNA panels at baseline are reasonable given the theoretical immunomodulation flare concern; repeat 8–12 weeks post-cycle if symptomatic.
• Coagulation panel — PT/INR, aPTT, fibrinogen, D-dimer in subjects in whom Thymalin is being deployed for thrombo-inflammatory pathology (severe pneumonia, post-COVID syndrome). Russian literature reports normalization of platelet aggregation and fibrinolytic balance.
• Allergy / IgE history — Document prior reactions to bovine protein, prior parenteral biologicals, atopic history before first administration. Consider tryptase baseline in subjects with mast-cell disease history.
• Vital signs during first administration — Blood pressure, heart rate, respiratory rate, temperature at baseline and at 15-, 30-, and 60-minute intervals after first dose to monitor for acute hypersensitivity and infusion-style reactions.
• Indication-specific monitoring — For pulmonary infection: chest imaging, oxygen saturation, sputum / NP swab where relevant. For COVID-19 adjunct: lymphocyte trajectory, IL-6, ferritin, D-dimer trajectory. For elderly geroprotection: comprehensive geriatric assessment (cognitive, functional, frailty index) at annual intervals.
• Age-appropriate cancer screening — Standard age-appropriate screening (mammography, colonoscopy, PSA, low-dose chest CT in heavy smokers, skin exam) before and during long-term geroprotective use, given the immunomodulatory action and the appropriate vigilance for malignancy that any long-term immune-modifying intervention warrants.

Commonly Stacked With

Within the Khavinson bioregulator framework, Thymalin is most often paired with the pineal preparation Epithalamin (or its synthetic short-peptide successors) and with other organ-specific bioregulators in long-term geroprotective protocols. In western research contexts, Thymalin is also stacked with defined-structure thymic and immune peptides for synergistic immunorehabilitation.

→ Check compound compatibility in the Stack Builder

Regulatory Status

Related Compounds

People researching Thymalin often also look at these:

Next Steps

Key References

1. Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):233-240. PMID: 14523363. (266-patient elderly geroprotective trial; 6–8-year follow-up; mortality reductions of 2.0-fold for Thymalin alone, 2.5-fold for Thymalin + Epithalamin combination, 4.1-fold for the six-year annual combination sub-cohort vs untreated controls.)
2. Khavinson VKh, Morozov VG. [Geroprotective effect of thymalin and epithalamin]. Adv Gerontol. 2002;10:74-84. Russian. PMID: 12577695. (Russian-language companion publication of the elderly geroprotective trial.)
3. Khavinson VKh, Kuznik BI, Ryzhak GA. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. Adv Gerontol. 2013;26(1):20-37. Russian. PMID: 24003726. (Long-term clinical results across the Khavinson bioregulator family — Thymalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin.)
4. Khavinson VK, Linkova NS, Kvetnoy IM, Polyakova VO, Drobintseva AO, Kvetnaya TV, Ivko OM. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull Exp Biol Med. 2020 Nov;170(1):118-122. doi: 10.1007/s10517-020-05016-z. PMID: 33237528. (In vitro demonstration that Thymalin activates differentiation of human hematopoietic stem cells toward the lymphoid lineage, providing a candidate mechanism for clinical hematopoietic-recovery applications.)
5. Khavinson VK, Kuznik BI, Tarnovskaya SI, Linkova NS. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19. Stem Cell Rev Rep. 2021 Feb;17(1):285-290. doi: 10.1007/s12015-020-10087-6. PMID: 33575961. (Review proposing thymic peptides including Thymalin for COVID-19 immunorehabilitation based on hematopoietic stem cell differentiation and immunomodulatory mechanisms.)
6. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020 Sep 24;25(19):4389. doi: 10.3390/molecules25194389. PMID: 32987757. (Computational and mechanistic review of Khavinson short peptides — including the dipeptides EW and KE released within the Thymalin complex — as candidate immunomodulators for COVID-19.)
7. Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022 Mar 30;23(7):3697. doi: 10.3390/ijms23073697. PMID: 35408963. (Italian-collaboration mechanistic study of Thymalin, Epitalon, Vilon, Thymogen, and Chonluten in human THP-1 monocytes; Khavinson Peptides act as inducers of TNF tolerance and anti-inflammatory modulators; one of the few non-Russian-affiliated mechanistic confirmations.)
8. Khavinson VK, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Ashapkin VV. The Use of Thymalin for Immunocorrection and Molecular Aspects of Biological Activity. Front Pharmacol. 2021;12:716947. doi: 10.3389/fphar.2021.716947. PMC8365293. (Narrative review summarizing 6–12-year Russian clinical data on Thymalin in pulmonary infection, viral disease, immunodepression after radiation and chemotherapy, and geroprotection.)
9. Kuznik B, Khavinson V, Shapovalov K, Lukyanov S, Smolyakov Y, Tereshkov P, Shapovalov Y, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol. 2021;11(4):360-367. doi: 10.1134/S2079057021040068. (Single-center Chita State Medical Academy trial — IRB-approved protocol no. 102, 15 May 2020 — in older severe-COVID-19 patients; Thymalin arm showed faster lymphopenia reversal, restoration of CD3+HLA-DR+, CD4+, B-, and NK-cell subpopulations, recovery of platelet/lymphocyte ratio, and reduced in-hospital mortality vs standard care.)
10. Khavinson VK, Kuznik BI, Volchkov VA, Rukavishnikova SA, Titova ON, Akhmedov TA, Trofimova SV, Ryzhak GA, Potyomkin VV, Saginbaev UR. Effect of thymalin on adaptive immunity in complex therapy for patients with COVID-19. Klinicheskaya Meditsina (Russian Journal). 2020;98(8):593-599. doi: 10.30629/0023-2149-2020-98-8-593-599. (Comparative IgG-to-SARS-CoV-2 dynamics with vs without Thymalin in COVID-19 patients.)
11. Lukyanov SA, Kuznik BI, Shapovalov KG, Khavinson VK, Smolyakov YN, et al. Thymalin as a Potential Alternative in the Treatment of Severe Acute Respiratory Infection Associated with SARS-CoV-2. Int J Immunol Immunother. 2020;7:055. (Severe-COVID-19 case treated with Thymalin 10 mg IM daily after failed lopinavir/ritonavir + hydroxychloroquine, with marked early clinical improvement.)
12. Morozov VG, Khavinson VKh. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997 Sep-Oct;19(9-10):501-505. doi: 10.1016/S0192-0561(97)00058-1. PMID: 9637345. (Foundational western-indexed paper describing Thymalin and the synthetic dipeptide derivative L-Glu-L-Trp / Thymogen, with reported activity on T-cell differentiation, T-cell recognition of peptide-MHC complexes, intracellular cyclic nucleotides, IL-2 and interferon excretion.)
13. Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID: 12374906. (Comprehensive Khavinson review of the peptide bioregulator program; Thymalin's immune-stimulating activity highlighted as the most prominent of its effects.)
14. Anisimov VN, Khavinson VKh, Morozov VG. Carcinogenesis and aging. IV. Effect of low-molecular-weight factors of thymus, pineal gland and anterior hypothalamus on immunity, tumor incidence and life span of C3H/Sn mice. Mech Ageing Dev. 1982 Jul;19(3):245-258. doi: 10.1016/0047-6374(82)90055-2. (Foundational Khavinson preclinical work supporting the geroprotection / carcinogenesis-attenuation framework that Thymalin clinical trials later built on.)
15. Kuznik BI, Makhakova GCh, Morozov VG, Pisarevskaia LI, Khavinson VKh. [Effect of thymalin on thrombocyte aggregation and the antiaggregation activity of the vascular wall in intact and thymectomized rats]. Biull Eksp Biol Med. 1986 Aug;102(8):200-202. Russian. PMID: 3754821. (Early characterization of Thymalin's effect on platelet hemostasis and the thymus-platelet axis; the 1980s foundation of the modern thrombo-inflammatory / COVID rationale.)
16. Khavinson VK, Lin'kova NS, Tarnovskaya SI. Short Peptides Regulate Gene Expression. Bull Exp Biol Med. 2016 Nov;162(2):288-292. doi: 10.1007/s10517-016-3596-7. PMID: 27909961. (Khavinson group's short-peptide DNA-binding / gene-expression-regulation hypothesis, the mechanistic frame underpinning the polypeptide-complex pharmacology argument for Thymalin.)
17. Khavinson V, Popovich I. Short Peptides Regulate Gene Expression, Protein Synthesis and Enhance Life Span. In: Vaiserman AM (ed.). Anti-aging Drugs: From Basic Research to Clinical Practice. RSC Drug Discovery Series No. 57. Royal Society of Chemistry; 2017. Chapter 20, pp. 496–513. doi: 10.1039/9781782626602-00496. (Book chapter elaborating the Khavinson short-peptide gene-expression hypothesis and its application to Thymalin and the bioregulator family.)
18. Khavinson V, Linkova N, Diatlova A, Trofimova S. Peptide Regulation of Cell Differentiation. Stem Cell Rev Rep. 2020 Feb;16(1):118-125. doi: 10.1007/s12015-019-09938-8. PMID: 31808038. (Mechanistic review of short-peptide regulation of cell differentiation, including thymic and hematopoietic lineages relevant to Thymalin's pharmacology.)
19. Linkova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VK. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bull Exp Biol Med. 2016 May;161(1):175-178. doi: 10.1007/s10517-016-3370-x. PMID: 27259484. (Khavinson short-peptide bioregulator activity on aging fibroblasts; complements the broader bioregulator framework Thymalin sits within.)
20. Khavinson VKh. Peptide medicines: past, present, future. Klinicheskaya Meditsina (Russian Journal). 2020;98(3):165-177. doi: 10.30629/0023-2149-2020-98-3-165-177. (Khavinson historical and prospective overview of the Russian peptide-bioregulator program — Thymalin, Epithalamin, Cortexin, Prostatilen, Retinalamin — developed at the Military Medical Academy named after S.M. Kirov.)